It’s been a few years since Amedisys has struck a deal at the scale of an AseraCare or Compassionate Care Hospice, reports Home Health Care News.
Scott Ginn, Amedisys’ vice president and CFO, said the reason for that is a combination of navigating a difficult M&A environment and the fact that it’s harder to source deals of that size.
“We’ve spent almost $700 million in acquisitions on the hospice side,” Ginn said. “We wanted to pause [and] make sure we integrate it. We did AseraCare in the middle of COVID, and now we want to see those ADCs start to return. It doesn’t mean we won’t look at hospice, but we’re probably one-and-half years behind where we thought we’d be, mainly because of COVID issues and around what’s happened with ADC. We’re still hunting for a nice home health deal – you’ve got to get through the diligence pieces.” Read more.
